498 related articles for article (PubMed ID: 35535675)
1. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
2. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
5. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
7. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
8. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
Tong F; Lu Y; Ma HF; Shen J
Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
13. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
15. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Decker T; Lüdtke-Heckenkamp K; Melnichuk L; Hirmas N; Lübbe K; Zahn MO; Schmidt M; Denkert C; Lorenz R; Müller V; Zahm DM; Mundhenke C; Bauer S; Thill M; Seropian P; Filmann N; Loibl S
Breast; 2023 Dec; 72():103575. PubMed ID: 37690320
[TBL] [Abstract][Full Text] [Related]
16. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J; Kettner NM; Rao X; Bishop CS; Bui TN; Wingate HF; Singareeka Raghavendra A; Wang Y; Wang J; Sahin AA; Meric-Bernstam F; Hunt KK; Damodaran S; Tripathy D; Keyomarsi K
Cancer Res; 2023 Oct; 83(19):3264-3283. PubMed ID: 37384539
[TBL] [Abstract][Full Text] [Related]
17. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
[TBL] [Abstract][Full Text] [Related]
18. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
19. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
20. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]